loading
Outlook Therapeutics Inc stock is traded at $1.71, with a volume of 982.99K. It is up +8.23% in the last 24 hours and down -3.39% over the past month. Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.58
Open:
$1.6
24h Volume:
982.99K
Relative Volume:
1.83
Market Cap:
$78.64M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.4275
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
-5.00%
1M Performance:
-3.39%
6M Performance:
-16.99%
1Y Performance:
-75.88%
1-Day Range:
Value
$1.57
$1.75
1-Week Range:
Value
$1.555
$1.90
52-Week Range:
Value
$0.87
$9.25

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name
Name
Outlook Therapeutics Inc
Name
Phone
(609) 619-3990
Name
Address
111 S. WOOD AVENUE, ISELIN, NJ
Name
Employee
23
Name
Twitter
Name
Next Earnings Date
2024-08-14
Name
Latest SEC Filings
Name
OTLK's Discussions on Twitter

Compare OTLK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
OTLK
Outlook Therapeutics Inc
1.71 78.64M 0 -51.50M -47.10M -4.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-02-24 Downgrade Chardan Capital Markets Buy → Neutral
Mar-27-24 Upgrade BTIG Research Neutral → Buy
Feb-15-24 Upgrade Chardan Capital Markets Neutral → Buy
Jan-25-24 Upgrade Guggenheim Neutral → Buy
Dec-27-23 Upgrade CapitalOne Equal Weight → Overweight
Aug-31-23 Downgrade Chardan Capital Markets Buy → Neutral
Aug-31-23 Downgrade H.C. Wainwright Buy → Neutral
Aug-30-23 Downgrade BTIG Research Buy → Neutral
Aug-30-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Aug-30-23 Downgrade CapitalOne Overweight → Equal Weight
Aug-30-23 Downgrade Guggenheim Buy → Neutral
Jul-13-23 Initiated CapitalOne Overweight
Apr-03-23 Initiated Guggenheim Buy
Feb-06-23 Initiated Cantor Fitzgerald Overweight
Oct-31-22 Initiated BTIG Research Buy
Sep-13-22 Initiated Chardan Capital Markets Buy
Sep-11-19 Initiated Ladenburg Thalmann Buy
May-16-19 Initiated Oppenheimer Outperform
Apr-22-19 Initiated Ascendiant Capital Markets Buy
View All

Outlook Therapeutics Inc Stock (OTLK) Latest News

pulisher
Jun 18, 2025

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event | OTLK Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Outlook Therapeutics, Inc. to Host Virtual Investor Lunch Break Event on June 25, 2025 - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - GlobeNewswire

Jun 18, 2025
pulisher
Jun 18, 2025

Outlook Therapeutics CEO Reveals Commercial Strategy and Key Milestones in Exclusive Investor Event - Stock Titan

Jun 18, 2025
pulisher
Jun 17, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Outlook LawsuitOTLK - ACCESS Newswire

Jun 17, 2025
pulisher
Jun 16, 2025

Outlook Launches Ophthalmic Bevacizumab In Germany And The UK - insights.citeline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 16, 2025
pulisher
Jun 13, 2025

Outlook Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 13, 2025
pulisher
Jun 13, 2025

Brookline Capital lowers Outlook Therapeutics stock price target on cash balance By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Brookline Capital lowers Outlook Therapeutics stock price target on cash balance - Investing.com Australia

Jun 13, 2025
pulisher
Jun 10, 2025

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Outlook Therapeutics Announces SMC Recommendation Of LYTENAVA For Treatment Of Wet AMD - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Outlook Therapeutics (OTLK) Gains SMC Approval for LYTENAVA in Scotland | OTLK Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - The Manila Times

Jun 10, 2025
pulisher
Jun 10, 2025

Outlook Therapeutics® Announces SMC Recommendation of - GlobeNewswire

Jun 10, 2025
pulisher
Jun 10, 2025

Breakthrough: Scotland NHS Approves First-Ever Licensed Bevacizumab Treatment for Wet AMD Patients - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Jane Street Group LLC Purchases 15,008 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Jun 10, 2025
pulisher
Jun 06, 2025

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jun 06, 2025
pulisher
Jun 06, 2025

Ascendiant Capital lowers Outlook Therapeutics stock price target to $21 - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

Ascendiant Capital lowers Outlook Therapeutics stock price target to $21 By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

Outlook Therapeutics (OTLK): Analyst Lowers Price Target but Mai - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Outlook Therapeutics (OTLK): Analyst Lowers Price Target but Maintains Buy Rating | OTLK Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 04, 2025

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities - GlobeNewswire Inc.

Jun 04, 2025
pulisher
Jun 03, 2025

Northern Trust Corp Sells 7,119 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Outlook Therapeutics launches LYTENAVA in Germany and UK By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Outlook Therapeutics® Announces Commercial Launch of - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Outlook Therapeutics Announces Commercial Launch Of Lytenava In Germany And UK For Treatment Of Wet AMD - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Outlook Therapeutics (OTLK) Launches LYTENAVA in European Markets | OTLK Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Outlook Therapeutics launches LYTENAVA in Germany and UK - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Outlook Therapeutics Launches LYTENAVA For Patients With Wet AMD In Germany And The UK - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD - The Manila Times

Jun 02, 2025
pulisher
May 31, 2025

Q3 EPS Forecast for Outlook Therapeutics Boosted by Analyst - Defense World

May 31, 2025
pulisher
May 30, 2025

Brokers Issue Forecasts for OTLK FY2026 Earnings - Defense World

May 30, 2025
pulisher
May 28, 2025

Metric Analysis: Outlook Therapeutics Inc (OTLK)’s Key Ratios in the Limelight - DWinneX

May 28, 2025
pulisher
May 25, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $10.20 Average Target Price from Brokerages - Defense World

May 25, 2025
pulisher
May 23, 2025

Outlook Therapeutics Announces New Stock and Warrant Offering - TipRanks

May 23, 2025
pulisher
May 23, 2025

Outlook Therapeutics (OTLK) Engages BTIG for Exclusive Offering Management | OTLK Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering | OTLK Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Outlook Therapeutics (OTLK) Announces $13M Public Offering - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Outlook Therapeutics Announces Pricing Of $13.0 Million Public Offering - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - GlobeNewswire

May 23, 2025
pulisher
May 23, 2025

Outlook Therapeutics Secures $13M Financing: Key Details of Share Offering and Double Warrant Coverage - Stock Titan

May 23, 2025
pulisher
May 23, 2025

Outlook Therapeutics (OTLK) Launches Public Offering of Stock an - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Outlook Therapeutics Reports Improved Financials Amid Challenges - TipRanks

May 23, 2025
pulisher
May 22, 2025

Outlook Therapeutics Plans Share Offering; Stock Declines After Hours - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Outlook Therapeutics announces public stock offering - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Outlook Therapeutics announces public stock offering By Investing.com - Investing.com Canada

May 22, 2025
pulisher
May 22, 2025

Outlook Therapeutics (OTLK) Launches Public Offering of Stock and Warrants | OTLK Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Outlook Therapeutics® Announces Proposed Public Offering of Comm - GuruFocus

May 22, 2025

Outlook Therapeutics Inc Stock (OTLK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Cap:     |  Volume (24h):